Monte Rosa Therapeutics

General Information

We are a biopharmaceutical company developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically-relevant proteins. We have developed a proprietary protein degradation platform, called QuEEN, that enables us to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates that are designed to eliminate therapeutically-relevant proteins in a highly selective manner. We believe our small molecule MGDs may give us significant advantages over existing therapeutic modalities, including other protein degradation approaches, by allowing us to target proteins that have been considered undruggable or inadequately drugged. We focus on therapeutic targets backed by strong biological and genetic rationale with the goal of discovering and developing novel precision medicines. These opportunities include oncology and non-oncology indications, including immunology, inflammation, neurological and genetic diseases. Our lead program is a series of selective and orally bioavailable GSPT1-directed MGD molecules, one of which we plan to evaluate in molecularly-defined subsets of Myc-driven cancers. We expect to select a development candidate in the second half of 2021 and submit an Investigational New Drug application, or IND, with the U.S. Food and Drug Administration, or the FDA, in the first half of 2022. Beyond our lead program, we have a number of discovery programs in our pipeline and intend to nominate at least two for lead optimization in 2021.

Employees: 75
Founded: 2019
Contact Information
Address 645 Summer Street, Suite 102, Boston, MA 02210, US
Phone Number (617) 949-2643
Web Address
View Prospectus: Monte Rosa Therapeutics
Financial Information
Market Cap $765.7mil
Revenues $0 mil (last 12 months)
Net Income $-43.9 mil (last 12 months)
IPO Profile
Symbol GLUE
Exchange NASDAQ
Shares (millions): 11.7
Price range $19.00 - $19.00
Est. $ Volume $222.3 mil
Manager / Joint Managers J.P. Morgan/ Cowen and Company/ Piper Sandler/ Guggenheim Securities
CO-Managers -
Expected To Trade: 6/24/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change